Danica Pension Livsforsikringsaktieselskab Buys New Stake in Bristol Myers Squibb Company $BMY

Danica Pension Livsforsikringsaktieselskab bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 165,023 shares of the biopharmaceutical company's stock, valued at approximately $9,509,000.

A number of other institutional investors also recently added to or reduced their stakes in BMY. waypoint wealth counsel acquired a new position in Bristol Myers Squibb during the 4th quarter valued at about $1,194,000. Life Cycle Investment Partners Ltd acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter worth approximately $34,406,000. Lazard Asset Management LLC lifted its stake in shares of Bristol Myers Squibb by 23.7% in the 1st quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company's stock worth $116,693,000 after acquiring an additional 368,193 shares during the period. Axxcess Wealth Management LLC boosted its holdings in shares of Bristol Myers Squibb by 27.4% in the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company's stock valued at $5,322,000 after acquiring an additional 21,196 shares in the last quarter. Finally, Asset One Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $4,075,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Piper Sandler started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued an "overweight" rating for the company. Bank of America lowered their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating on the stock in a research report on Friday, July 10th. Jefferies Financial Group downgraded Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research note on Wednesday, August 5th. Cantor Fitzgerald restated a "neutral" rating and issued a $59.00 price objective (up from $54.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Finally, Guggenheim reaffirmed a "buy" rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of "Moderate Buy" and a consensus target price of $66.06.

Bristol Myers Squibb Trading Up 2.2%

NYSE:BMY opened at $66.07 on Wednesday. The stock has a market cap of $134.97 billion, a PE ratio of 14.55, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.10. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The stock's 50-day moving average is $59.94 and its two-hundred day moving average is $59.14.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period in the prior year, the firm earned $1.46 earnings per share. The firm's revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 55.51%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source